越大越好吗？香氛剂5与10mg治疗失眠症的疗效及安全性分析。

IF 1.8 Q3 PHARMACOLOGY & PHARMACY

International Journal of Pharmacy Practice Pub Date : 2025-09-27 DOI:10.1093/ijpp/riaf077

Eugene Chang, Aaron M Tejani

{"title":"越大越好吗？香氛剂5与10mg治疗失眠症的疗效及安全性分析。","authors":"Eugene Chang, Aaron M Tejani","doi":"10.1093/ijpp/riaf077","DOIUrl":null,"url":null,"abstract":"Objective: To assess the rationale for using lemborexant 10 mg as a starting dose or for those with partial response to 5 mg for the management of insomnia.Methods: A review of MEDLINE, regulatory reports, and Canadian Agency for Drugs and Technologies in Health data was conducted.Key findings: Lemborexant 10 mg as an initial dose offers minimal improvement in sleep metrics over 5 mg but increases somnolence risk. No evidence supports dose escalation for partial responders to 5 mg.Conclusion: Lemborexant 10 mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10 mg in insomnia patients.\",\"authors\":\"Eugene Chang, Aaron M Tejani\",\"doi\":\"10.1093/ijpp/riaf077\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: To assess the rationale for using lemborexant 10 mg as a starting dose or for those with partial response to 5 mg for the management of insomnia.Methods: A review of MEDLINE, regulatory reports, and Canadian Agency for Drugs and Technologies in Health data was conducted.Key findings: Lemborexant 10 mg as an initial dose offers minimal improvement in sleep metrics over 5 mg but increases somnolence risk. No evidence supports dose escalation for partial responders to 5 mg.Conclusion: Lemborexant 10 mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.\",\"PeriodicalId\":14284,\"journal\":{\"name\":\"International Journal of Pharmacy Practice\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmacy Practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/ijpp/riaf077\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/ijpp/riaf077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

目的：评估使用leleborexant 10mg作为起始剂量或对5mg有部分反应的患者治疗失眠的合理性。方法：对MEDLINE、监管报告和加拿大药物和健康技术机构的数据进行回顾。主要发现：lelemborexant 10毫克作为初始剂量对睡眠指标的改善作用小于5毫克，但会增加嗜睡的风险。没有证据支持部分反应者增加剂量至5mg。结论：Lemborexant 10mg通常不建议作为初始剂量或升级剂量，因为较高的危害风险和不太可能的临床效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Is bigger better? Analysis of efficacy and safety of lemborexant 5 versus 10 mg in insomnia patients.

Objective: To assess the rationale for using lemborexant 10 mg as a starting dose or for those with partial response to 5 mg for the management of insomnia.

Methods: A review of MEDLINE, regulatory reports, and Canadian Agency for Drugs and Technologies in Health data was conducted.

Key findings: Lemborexant 10 mg as an initial dose offers minimal improvement in sleep metrics over 5 mg but increases somnolence risk. No evidence supports dose escalation for partial responders to 5 mg.

Conclusion: Lemborexant 10 mg is generally not advisable as an initial or escalated dose due to higher harm risk and unlikely clinical benefit.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Pharmacy Practice PHARMACOLOGY & PHARMACY-

CiteScore

2.90

自引率

5.60%

发文量

146

期刊介绍： The International Journal of Pharmacy Practice (IJPP) is a Medline-indexed, peer reviewed, international journal. It is one of the leading journals publishing health services research in the context of pharmacy, pharmaceutical care, medicines and medicines management. Regular sections in the journal include, editorials, literature reviews, original research, personal opinion and short communications. Topics covered include: medicines utilisation, medicine management, medicines distribution, supply and administration, pharmaceutical services, professional and patient/lay perspectives, public health (including, e.g. health promotion, needs assessment, health protection) evidence based practice, pharmacy education. Methods include both evaluative and exploratory work including, randomised controlled trials, surveys, epidemiological approaches, case studies, observational studies, and qualitative methods such as interviews and focus groups. Application of methods drawn from other disciplines e.g. psychology, health economics, morbidity are especially welcome as are developments of new methodologies.